Advanced Therapies Congress presents:
CAR-T day
Thursday 18th March | 3pm-5pm GMT
CONFIRMED SPEAKERS
PANEL DISCUSSION: TACKLING SOLID TUMOURS
3pm-4pm GMT
Novel strategies for overcoming hurdles to solid tumor gene modified cell therapy will be discussed
• Hurdles to solid tumor cell therapy and novel strategies to overcome
• Autologous and allogeneic cell therapy for solid tumors
• Potential role for combination cellular therapies
Chair: Stefanos Theoharis , CBO, Bone Therapeutics (confirmed)
Emanuele Ostuni , Head of Europe, Cell & Gene Therapy, Novartis (confirmed)
Prasad Adusumilli , Attending Surgeon, Memorial Sloan Kettering Cancer Center (confirmed)
Steve Kanner , CSO, Caribou Biosciences (confirmed)
PANEL DISCUSSION: AUTOLOGOUS VS ALLOGENEIC
4pm-5pm GMT
PANEL: Autologous vs Allogeneic: Identify the challenges and opportunities for cost teffective and efficacious therapies
• Rise of allogeneic cells and allo-approaches to oncology & non-oncology
• Tools and technologies to make this a reality
Chair: Albert Ribickas , Bone Marrow Transplant Laboratory Manager, Moffitt Cancer Center (confirmed)
Stefanos Theoharis , CBO , Bone Therapeutics (confirmed)
Emanuele Ostuni , Head of Europe, Cell & Gene Therapy, Novartis (confirmed)
Jakob Dupont , Global Head of R&D, Atara Biotherapeutics (confirmed)
Organiser
